Understanding where trade-remedy exposure lands in a large multinational meat group requires looking past the operating brands to the intermediate holding layers. In structures that route ownership through Luxembourg and other holding jurisdictions, the entity that contracts for cross-border sales is frequently not the entity that the public associates with the brand, and that distinction matters for Section 301 and antidumping exposure analysis.
The analytical method is to trace the chain from the ultimate parent down to the entities that take title at the border, since duty liability attaches to the importer of record and trade-remedy margins are calculated on the producer or exporter actually shipping. Holding companies that perform financing and IP functions rarely appear on customs documentation, but they shape transfer pricing and therefore the constructed value calculations that surface in remedy proceedings.
The practical takeaway for analysts is to build the structure chart before modelling tariff impact. Aggregate group exposure is less informative than entity-level exposure mapped to product classification and origin. Where processing occurs across multiple jurisdictions, substantial transformation and origin rules can shift the answer materially, and the holding architecture often signals which planning options the group has already taken.